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Abstract Province-wide population-based administrative
health data from British Columbia (BC), Canada (popula-
tion: approximately 4.5 million) were used to estimate the
incidence and prevalence of multiple sclerosis (MS) and
examine potential trends over time. All BC residents
meeting validated health administrative case definitions for
MS were identified using hospital, physician, death, and
health registration files. Estimates of annual prevalence
(1991–2008), and incidence (1996–2008; allowing a 5-year
disease-free run-in period) were age and sex standardized
to the 2001 Canadian population. Changes over time in
incidence, prevalence and sex ratios were examined using
Poisson and log-binomial regression. The incidence rate
was stable [average: 7.8/100,000 (95 % CI 7.6, 8.1)], while
the female: male ratio decreased (p = 0.045) but remained
at or above 2 for all years (average 2.8:1). From
1991–2008, MS prevalence increased by 4.7 % on average
per year (p\ 0.001) from 78.8/100,000 (95 % CI 75.7,
82.0) to 179.9/100,000 (95 % CI 176.0, 183.8), the sex
prevalence ratio increased from 2.27 to 2.78 (p\ 0.001)
and the peak prevalence age range increased from 45–49 to
55–59 years. MS incidence and prevalence in BC are
among the highest in the world. Neither the incidence nor
the incidence sex ratio increased over time. However, the
prevalence and prevalence sex ratio increased significantly
during the 18-year period, which may be explained by the
increased peak prevalence age of MS, longer survival with
MS and the greater life expectancy of women compared to
men.
Keywords Multiple sclerosis  Incidence  Prevalence 
Epidemiology  Sex ratio  Administrative health data
For the CIHR Team in the Epidemiology and Impact of Comorbidity
on MS. Members in this team is listed in acknowledgments.
& Elaine Kingwell
elainejk@mail.ubc.ca
1 Faculty of Medicine (Neurology), UBC Hospital, University
of British Columbia, 2211 Wesbrook Mall, Vancouver,
BC V6T 2B5, Canada
2 Departments of Internal Medicine & Community Health
Sciences, University of Manitoba, Winnipeg, MB, Canada
3 Departments of Psychiatry and Medicine, Dalhousie
University, Halifax, NS, Canada
4 Department of Medicine and of Epidemiology, Biostatistics
and Occupational Health, McGill University, Montreal, QC,
Canada
5 Faculty of Rehabilitation Medicine, University of Alberta,
Edmonton, AB, Canada
6 Faculty of Nursing, University of Alberta, Edmonton, AB,
Canada
7 Surveillance and Assessment Branch, Alberta Health,
Government of Alberta, Edmonton, AB, Canada
8 Department of Clinical Neurosciences and Community
Health Sciences, Hotchkiss Brain Institute and O’Brien
Institute for Population Health, University of Calgary,
Calgary, AB, Canada
9 Department of Medicine (Neurology), Dalhousie University,
Halifax, NS, Canada
10 Department of Community Health Sciences, University of
Manitoba, Winnipeg, MB, Canada
11 Departments of Community Health Sciences and Medical
Microbiology, University of Manitoba, Winnipeg, MB,
Canada
123
J Neurol (2015) 262:2352–2363
DOI 10.1007/s00415-015-7842-0
Background
Multiple sclerosis (MS), a chronic, debilitating disease of
the central nervous system, is the leading cause of non-
traumatic disability in young adults [1]. It is estimated that
more than two million people live with this disease world-
wide [1], although the incidence and prevalence vary geo-
graphically [2–4]. Furthermore, reports of recent increases
in the incidence and prevalence, and in the ratio of women to
men with MS, have been inconsistent across regions [5–7].
The need for current and reliable estimates of MS
incidence and prevalence has been highlighted as a public
health and research priority, essential to support the plan-
ning and prioritization of health care services and to reduce
the overall burden of chronic disease [1, 8, 9].
Valid and reliable methods are required when estimating
incidence and prevalence so that regional estimates can be
compared. Validated case definitions that use population-
based administrative data offer this opportunity where such
data are available. Canada has a universal publicly funded
health care system and, in its western-most province British
Columbia (BC), health claims data for the entire population
are captured. No estimates of the prevalence of MS in BC
using population-based linked health administrative data
have been reported, and the incidence of MS in BC has not
been previously estimated by any method.
We aimed to estimate the incidence and prevalence of
MS in BC, Canada using previously validated case defi-
nitions of MS [10, 11] based on health administrative data.
Also, we described the demographics of the incident and
prevalent cases and temporal changes in their characteris-
tics including the sex ratio.
Methods
British Columbia is situated on the west coast of Canada.
Its population of 4.5 million people represents 13 % of the
Canadian population. The publicly funded provincial
health care programme is compulsory for residents; a
lifelong unique personal health care number is assigned
and is linked through provincial administrative databases to
all hospital admissions, physician visits, prescription dis-
pensations, births, deaths, and health care plan registration
and cancellation dates.
Anonymized linked BC health administrative data files
used in this study included the Hospital Admission and
Discharge database (hospital admission dates and diagnosis
codes) [12], and the Medical Services Plan Billing
(physician visits and billing diagnosis codes) [13], These
databases store data on physician billing or medical ser-
vices claims (‘claims’) that have been submitted for pay-
ment, including the type of service provided, when and to
whom the service was provided, and the diagnoses related
to the physician visit or hospital admission (coded via
International Classification of Disease (ICD-9 or ICD-10-
CA)). PharmaNet (dispensed prescriptions coded by Health
Canada’s Drug Identification Numbers) [14], and Vital
Statistics (death dates) [15] were also accessed. Registra-
tion Premium and Billing files [16] provided demographic
data: registration dates in the provincial health care plan
confirmed residency in BC; socioeconomic status (SES)
was expressed as quintiles of average neighbourhood
income based on regional income levels (prepared by
Statistics Canada using postal codes [17]).
We utilized a previously linked data platform which
included all residents of BC with C3 MS-related claims.
Linked data were available from 1986, apart from ICD
codes from physician visits which were available starting
in 1991. Prescription data were accessed for descriptive
purposes only, and were available starting in 1996. Follow-
up continued to the end of 2010 for the majority of those in
the dataset, with the remainder followed to the end of 2008.
MS cases were identified using administrative case
definitions, which have previously been validated in two
Canadian provinces (Manitoba and Nova Scotia) [10, 11],
and are based on hospital and physician-derived diagnostic
codes. The primary case definition used was C7 hospital or
physician claims specifically for MS for people who were
resident in BC for[3 years following their first demyeli-
nating disease (‘MS-related’) claim (i.e. a claim for MS,
optic neuritis, acute transverse myelitis, acute disseminated
encephalomyelitis, demyelinating disease of the CNS
unspecified, other acute disseminated demyelination, or
neuromyelitis optica), and C3 MS claims for those
with B3 years of residency. When validated against the
clinical MS definition, this algorithm was found to provide
the best balance of sensitivity and specificity compared to a
series of alternative administrative case definitions. For the
validation population (Nova Scotia, Canada), all of whom
had at least one claim for a demyelinating disease, this
definition had a sensitivity of 88 % and specificity of 68 %;
the specificity would, however, be substantially higher in
the general population given that[99.9 % of individuals
have no demyelinating claims [11, 18]. A second case
definition was also used which required C3 MS claims
irrespective of the cumulative residency in BC, for which
previous validation has demonstrated greater sensitivity
(95 %) but less specificity (48 %) among those with at
least one demyelinating claim [11].
Point prevalence was estimated annually on July 1st,
from 1991 to 2008, and incidence estimates were generated
from 1996 to 2008, with inclusion of claims up to 2010.
Both incidence and prevalence were calculated per 100,000
people using the BC mid-year population and were age and
sex standardized to the 2001 Canadian population, for
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consistency to prior Canadian work [10, 11, 19]. The 95 %
confidence intervals (CI) were calculated based on the
Gamma distribution [20]. Incidence estimates began in
1996 because at least 5 years residency with no MS-related
claim was required to meet the incident case definition.
Once this definition was met, the date of the first MS-related
claim was considered the incidence date of MS diagnosis.
Individuals who immigrated to the province after the study
start were followed from the date of their first registration in
the universal BC health care plan; as with cases that were
resident from study start, a 5-year residency with no MS-
related claim was required to be counted as an incident case.
Description of the incident cases included sex, age, SES,
time to meet the case definition, and dispensation of a MS
disease-modifying drug (DMD) within 3 years of the
incident claim. This time window was chosen because the
diagnosis date falls within 3 years of the incident claim for
approximately 75 % of MS cases [10]. Cases that were
prevalent on July 1st 2008 were described by sex and age,
SES and history of a DMD prescription (including beta
interferon-1a, beta interferon-1b, glatiramer acetate and
natalizumab). The distribution of cases across the SES
quintiles was compared to the expected (even) distribution.
Changes in the incidence rate and prevalence over the
observation period were investigated using Poisson (with
the BC population included as an offset) and log-binomial
regression, respectively. The models included an interac-
tion term between year and sex. Potential differences in the
distribution over socioeconomic quintiles were assessed
using a Chi-Squared test of homogeneity.
Follow-up data for the years 2009 and 2010 were
unavailable for some individuals who were alive and res-
ident in BC at the end of 2008 but had not yet met the MS
case definition. To assess the potential impact of this
missing 2 years of follow-up data on the findings, the
numbers of potentially missed incident and prevalent cases
were calculated by assuming every individual with missing
follow-up data would have met the case definition and the
estimates and comparisons were repeated.
Statistical analyses were performed using R: A Language
and Environment for Statistical Computing v.2.15 (R Foun-
dation for Statistical Computing, Vienna, Austria; 2012).
This study was approved by the University of British
Columbia’s Clinical Research Ethics Board (approval # H10-
01361).BCMinistry ofHealth,BCVital StatisticsAgency and
BC PharmaNet approved access to administrative health data.
Results
Between 1996 and 2008, 4,222 BC residents met the
incident case definition of C7 MS claims (or C3 MS
claims for those with B3 years of residency in BC) and at
least 5 years of residency before their first MS-related
claim. The standardized annual incidence rate was 7.8
(95 % CI 7.6, 8.1) per 100,000 people; 11.5 (95 % CI 11.1,
11.9) for women and 4.1 (95 % CI 3.8, 4.3) for men. The
more sensitive case definition of C3 MS claims identified
5876 incident cases for a standardized annual incidence
estimate of 10.9 (95 % CI 10.6, 11.2) per 100,000.
Characteristics of the incident cases are summarized in
Table 1; the sex, age and SES distributions were similar
regardless of the case definition used. Women made up
approximately three quarters of the incident cases. The
overall mean age at the first MS-related claim was lower
for women (44 years) than for men (46 years) (p\ 0.001).
The distribution of cases across the SES quintiles differed
at the time of the incident claim, with more cases in the
middle and higher SES quintiles, but the absolute differ-
ences were small. Among all incident cases (using the
primary definition), 27 % filled a prescription for a DMD
within 3 years of their incident claim; this proportion
increased between 1996 and 2000 from 10 to 32 %; the
proportion with prescriptions within 3 years then remained
stable at 31–33 % from 2000 to 2007 (the last calendar
year with 3 years of follow-up).
The median number of years between the first MS-re-
lated claim and fulfilling criterion for the primary case
definition was 1.3 years overall; 1.2 years for women and
1.0 years for men. As the follow-up time decreased over
the observation period, the median time to reach criterion
naturally decreased; the longest was 2.1 years (interquartile
range: 0.8, 5.3) in 1996 when up to 15 years of follow-up
data were available. Using the more sensitive case defini-
tion, 75 % of cases reached criterion in 1.8 years (median
0.4 years) when up to 15 years of data were available.
Although there were small fluctuations in the annual
incidence rate (Fig. 1a, b), there was no evidence of an
increase in incidence between 1996 and 2008 regardless of
the case definition used. The average female to male
incidence ratio across all years was 2.8 (95 % CI 2.6, 3.0).
This ratio varied by calendar year; the interaction between
sex and year was statistically significant (p = 0.045) with a
small decrease in the incidence rate in women, while the
rate remained stable in men (Table 2).
On July 1st 2008, there were 8546 people with MS
living in BC and the standardized prevalence per 100,000
people was 179.9 (95 % CI 176.0, 183.8). The prevalence
estimates for each year by sex and the sex ratio for
1991–2008 are shown in Table 3. With the more sensitive
case definition, the standardized prevalence on July 1st
2008 was 235.8 (95 % CI 231.4, 240.3), and an estimated
11,184 cases were living in BC on the point prevalence
date.
The average age of the 8546 prevalent cases was
52 years and 74 % were women. As observed for the
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incident cases, a comparison across the SES groups
revealed an uneven distribution of prevalent MS cases with
more prevalent MS cases in the higher quintiles of SES
than in the lower quintiles, but small absolute differences.
Sex, age and SES distributions were similar for the
prevalent cases identified by the alternative administrative
case definitions (Table 1). At least 29 % of the prevalent
cases had received a prescription for a DMD at some point
during their follow-up (or 22 % of cases identified by the
more sensitive definition).
The prevalence of MS increased over the 18-year obser-
vation period by an average of 4.7 % per year (p\ 0.001),
and the sex prevalence ratio increased from 2.27 in 1991 to
2.78 in 2008 (p\ 0.001) (Fig. 2a, b). Overall, the peak age
Table 1 Characteristics of the
incident (1996–2008) and
prevalent (2008) multiple
sclerosis cases in British
Columbia, Canada





Women 3124 (74) 4315 (73)
Men 1098 (26) 1561 (27)
Age at incidence, years
Mean (SD) 44.3 (13.2) 44.7 (13.4)
Median (1st quartile, 3rd quartile) 43.4 (35.2, 51.7) 43.8 (35.6, 52.4)
Time to meet case definition, years
Mean (SD) 2.1 (2.2) 1.0 (1.7)
Median (1st quartile, 3rd quartile) 1.3 (0.5, 2.9) 0.4 (0.1, 1.1)
Prescription for a DMD, n (%)
Ever 1411 (33) 1432 (24)
Within 3 years of incident claim 1143 (27) 1156 (20)
SES quintile at incident claim, n (%)a
Lowest 759 (18)* 1050 (18)*
Second lowest 766 (18) 1091 (19)
Middle 902 (21) 1228 (21)
Second highest 857 (20) 1209 (21)
Highest 842 (20) 1163 (20)
Unknown 96 (2) 135 (2)





Women 6313 (74) 8206 (73)
Men 2233 (26) 2978 (27)
Age, years
Mean (SD) 52.3 (12.6) 52.3 (12.9)
Median (1st quartile, 3rd quartile) 52.3 (43.8, 60.5) 52.1 (43.7, 60.5)
Prescription of a DMD, n (%)
Ever 2485 (29) 2516 (22)
SES quintile, n (%)a
Lowest 1541 (18)* 2028 (18)*
Second lowest 1612 (19) 2090 (19)
Middle 1745 (20) 2257 (20)
Second highest 1782 (21) 2352 (21)
Highest 1727 (20) 2272 (20)
Missing 139 (2) 185 (2)
SD standard deviation, DMD disease-modifying drug, SES socioeconomic status
* p B 0.001
a Percentages may not sum to 100 due to rounding. Chi-squared test of homogeneity was used to compare
SES quintiles to an expected equal distribution across the quintiles (cases with missing SES were excluded)
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of prevalentMS cases increased over time from 45–49 years
in the early 1990s to 55–59 years in 2008 (Fig. 3).
Among those with missing follow-up information for
2009–2010, there were 254 individuals with C1 demyeli-
nating claim by the end of 2008 that had not yet met the
primary case definition and 74 who had not yet met the
more sensitive definition. These extra cases could poten-
tially have increased the MS prevalence estimate for 2008,
had complete follow-up data to 2010 been available. The
maximum potential impact is an underestimate of the 2008
prevalence by up to 5.3/100,000 (or 1.6/100,000 using
the C3 claim definition). The average annual 1996–2008
incidence may have been underestimated by up to 0.2 cases
per 100,000, while the estimated incidence using the
alternative case definition would not have been affected.
When all of these potential cases were assumed to have met
definition and included in the estimates and comparisons,
all findings related to changes over time and characteristics
of the incident and prevalent cases remained the same.
Discussion
The prevalence of MS in BC, Canada has risen steadily and
substantially, from 78.8/100,000 in 1991 to 179.9/100,000
in 2008. The incidence rate in BC remained stable over the
study period, averaging 7.8 per 100,000 new cases of MS




sclerosis cases identified by the
primary case definition (a) and
the more sensitive but less
specific case definition (b) in
British Columbia, Canada.
Note: The apparent increased
incidence in the final year
observed in a is a result of the
case criterion; all potential
incident cases for that year
had B3 years of follow-up
available to study end and
therefore required only 3 claims
to meet case definition
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other parts of the world [1–4]. The prevalence sex ratio
increased over time; however, the incidence sex ratio,
which averaged 2.8:1, did not increase.
Methodological differences make direct comparisons
with earlier studies of MS prevalence in BC difficult. Other
than a study based on self-reported MS [21], the last pro-
vince-wide estimate of MS prevalence, which used clini-
cally confirmed definitions, was 93.3/100,000 in 1982 [22].
Our estimates for 1991 (78.8/100,000) and 1992 (101.1/
100,000) are compatible with this estimate from 10 years
earlier. There are no previous estimates of MS incidence in
BC with which to compare our observations. However,
using the same validated administrative MS case defini-
tions age standardized to the same population, a similar
annual incidence rate was recently found in central Canada
[10] (11.4/100,000 in Manitoba using the more sensitive
case definition). While a somewhat higher annual incidence
was found in eastern Canada [11] (9.8/100,000 in Nova
Scotia using our primary case definition), the 95 % confi-
dence intervals overlapped with those in our study. BC,
Manitoba and Nova Scotia are home to approximately
19 % of the Canadian population; extrapolating the com-
bined estimate from these provinces (weighted by their
relative population) to Canada, which had a population of
35.5 million in 2014, would mean that approximately 3000
new MS cases are diagnosed each year, or 8 new cases per
day. Furthermore, extrapolating the combined prevalence
estimate (200/100,000) from the three provinces would
mean that approximately 71,000 people are living with MS
in Canada.
Table 2 Number of incident cases and incidence rate of multiple sclerosis per 100,000 population per year (1996–2008) in British Columbia,
Canada by sex and calendar year
Year Women Men All Incidence sex
ratio (95 % CI)a
Cases/popul. Crude IR (95 % CI)
[standardized IR]
Cases/popul. Crude IR (95 % CI)
[standardized IR]
























































































































































































IR incidence rate, Popul. population (denominator), CI confidence interval
a Crude incidence sex ratio (incidence rate in women: incidence rate in men)
b The apparent increase in incidence in 2008 is due to the case criterion; as of 2008 all potential cases required only 3 claims, unlike in previous
years, because B3 years of follow-up remained
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Our observations that the prevalence of MS has been
increasing by approximately 4.7 % per year in BC, and that
the age of the prevalent population has risen have impor-
tant implications for broader society, including govern-
ments and health care planners. We also found a gradual
increase in the proportion of women to men living with
MS; this is compatible with recent observations from
elsewhere in Canada [10, 11] and the UK [23], and is likely
due to the changing demographics (older mean age) of the
general population and the greater life expectancy of
women compared to men.
The rising prevalence in BC cannot be explained by
increasing numbers of new MS cases; our incidence rates
remained relatively stable over the 13-year period despite
Table 3 Number of prevalent cases and prevalence of multiple sclerosis per 100,000 population on July 1st (1991–2008) in British Columbia,
Canada by sex and calendar year
Year Women Men All Prevalence sex
ratio (95 % CI)a
Cases/
popul.




















































































































































































































































PP point prevalence, Popul. population (denominator), CI confidence interval
a Crude prevalence sex ratio (prevalence proportion in women: prevalence proportion in men)
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changes in MS diagnostic criteria [24] and increasing
availability of disease-modifying drugs. While this seems
in contrast to some other regions of the world where recent
increases in incidence rates have been reported [5], a stable
incidence rate has also been found over a similar time
period in other Canadian provinces [10, 11, 19, 25, 26] and
the UK [23]. Taken together with our findings, this sug-
gests that the incidence of MS has stabilised in some areas
over recent years. In the absence of increasing incidence,
the rising prevalence may reflect longer disease duration
due to earlier diagnosis, improved survival with MS or
both. Survival has improved for both the BC general
population and for people with MS in BC over the past
30 years [27]. Similarly, improved survival has been found
in other MS populations, including those from Denmark
[28] and Norway [29]. Immigration of prevalent cases can
also influence prevalence trends and the population of
British Columbia increased by nearly 30 % between 1991
and 2008, mostly due to immigration from other Canadian
provinces and other countries. The prevalence estimates
include MS cases that were resident throughout, as well as
those that immigrated to BC, during the observation period.
Newly immigrant prevalent cases would have contributed
to the increasing prevalence over time if there was a greater
proportion of MS cases among those immigrating to BC.
The average age at the time of the incident MS-related
claim was 44 years. This age is comparable to that recorded
in other Canadian provinces [10, 11] and was found to be
within 3 years of the MS diagnosis date from medical charts
or by personal report for 74 and 76 % of cases, respectively
[10]. It is also equivalent to that identified as the first date of




identified by the primary case
definition (a) and the more
sensitive but less specific case
definition (b) in British
Columbia, Canada
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cases of MS in the UK [23]. While the date of diagnosis, or
of first medical recognition, is frequently used to measure
MS incidence [2–4], symptom onset can often occur several
years before the disease is first recognized or diagnosed.
Notably, while others have reported increases in the
incidence ratio of women to men with MS [6], we found no
evidence of such a trend in BC. Rather, we observed a
decrease in this ratio over time, although the absolute
differences were small. Nonetheless, the more consistently
observed sex differences for MS were evident; nearly three
quarters of incident cases in BC were women and men
were approximately 3 years older than women at the time
of the first MS-related claim reflecting typical differences
in onset age between sexes.
We observed a small difference in the distribution of cases
across the socioeconomic quintiles, with a greater proportion
of both incident and prevalent cases in the upper quintiles and
fewer in the lower. Similar observations have been made in
the past [30–34], although others have reported either no
relationship or a negative association with SES [35].
Approximately, one-third of incident or prevalent MS
cases filled a prescription for a DMD during the study
period, stabilizing from the year 2000 onwards. This pro-
portion may seem low, particularly when compared to a
previous estimate (73–85 %) derived from a volunteer
sample of patients recruited from Canadian MS treatment
centres [36]. However, our proportion was derived from
population-based rather than clinic-based data, the first
DMD (interferon beta-1b) was only approved for use in
Canada in 1995, and not all individuals with MS would
have been eligible for treatment (including those unable to
walk, those without relapses and those with a primary
progressive disease course). Thus, it is likely that our data
provide a realistic representation of DMD use in the British
Columbian MS population over the study period.
The strengths of our study include the use of adminis-
trative health data, which represents the entire BC popu-
lation, and spans nearly two decades allowing us to assess
temporal trends. Furthermore, we used two previously
validated MS case definitions to generate these estimates
[10, 11]. The primary definition was identified as the best
in terms of balance between specificity and sensitivity
among candidate validated MS case definitions [11]. The
secondary definition generated higher estimates due to its
Fig. 3 Age-specific prevalence of multiple sclerosis identified by the primary case definition per 100,000 population by select years (1992, 1996,
2000, 2004 and 2008) in British Columbia, Canada
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greater sensitivity, but may have included a greater pro-
portion of false positives. Estimates generated by the pri-
mary definition could be more useful when it is important
to minimize the risk of including people without MS,
whereas the estimates from the more sensitive definition
are likely more useful for estimating burden of disease and
for health care planning. Although these MS case defini-
tions were not validated specifically using the BC admin-
istrative data, the algorithms have been validated in Nova
Scotia and Manitoba [10, 11]. Furthermore, similar 7-claim
administrative case definitions of MS derived from
administrative data in Ontario, Canada were validated in a
primary care dataset in that province and found to have
excellent performance [18]. The structure of the Canadian
public health care system and the methods for coding
physician and hospital visits in administrative health data
are consistent between these three provinces and BC,
which suggests that the case definitions would perform well
and can be reliably applied in BC. The BC administrative
health databases have been used, both independently and
combined with equivalent data from other Canadian pro-
vinces, to identify and study other chronic diseases such as
diabetes and hypertension [37–39].
Health administrative data have limitations. Although
we allowed a five-year claim-free run-in period to capture
incident cases, it remains possible that prevalent benign
MS cases that rarely interacted with the medical system
were misclassified as incident. Ascertainment is a common
problem with MS incidence studies due to the inevitable
time-lag between symptom onset and recognition of the
disease; the estimated incidence may be affected by
incomplete ascertainment towards the end of follow-up.
Similarly, the prevalence estimates for the earliest years
(1991 and 1992) should be treated cautiously; atypical
prevalent cases with infrequent contact with the medical
system could have been missed in these years. On the other
hand, although we had missing follow-up data for up to 254
potential MS cases and could not confirm that they met
criteria with follow-up to 2010, the estimates were not
notably impacted.
We were unable to consider ethnicity, or country of
origin. Although most BC residents are of European
ancestry, BC has a higher proportion of residents of non-
European origin than other Canadian provinces. The pro-
portion with European ancestry has declined over time,
from 82 % of the BC population in 1996 [40] to 75 % in
2006 [41]; people of Asian ancestry represent the largest
minority group. The somewhat lower MS incidence rate in
BC compared to that in Eastern Canada [11] might be
explained by differences in the ethnic composition of the
source populations [41].
In summary, BC has a high incidence of MS which has
remained stable for more than a decade. However, as
elsewhere in Canada, the prevalence and the peak age of
the MS population have increased significantly. Popula-
tion-based administrative health databases and validated
case definitions of MS using health claims data provide a
reliable, accessible and cost effective means of monitoring
the incidence and prevalence of MS.
Acknowledgments This study was supported by the Canadian
Institutes of Health Research (CIBG 101829); the Rx&D Health
Research Foundation; and a Don Paty Career Development Award
from the MS Society of Canada (to RAM). We thank the BC Ministry
of Health, BC Vital Statistics Agency and BC PharmaNet for
approval and support with accessing provincial data; and Population
Data BC for facilitating approval and use of the data.
CIHR Team in the Epidemiology and Impact of Comorbidity on
Multiple Sclerosis Ruth Ann Marrie, MD, Ph.D., FRCPC
(University of Manitoba, Principal Investigator); John D. Fisk, Ph.D.
(Dalhousie University, Co-principal Investigator and Site Investiga-
tor); Sharon Warren, Ph.D. (University of Alberta, Co-principal
Investigator and Site Investigator); Christina Wolfson, Ph.D. (McGill
University, Co-principal Investigator and Site Investigator); Helen
Tremlett, Ph.D. (University of British Columbia, Co-principal
Investigator and Site Investigator); James Blanchard, MD, MPH,
Ph.D. (University of Manitoba, Co-investigator); Lawrence Elliott,
MD, M.Sc. (University of Manitoba, Co-investigator); Bo Nancy Yu,
MD, Ph.D. (University of Manitoba, Co-investigator); Virender Bhan,
MBBS, FRCPC (Dalhousie University, Co-investigator); Joanne
Profetto-McGrath, Ph.D., RN (University of Alberta, Co-investiga-
tor); Scott Patten, MD, Ph.D. (University of Calgary, Co-investiga-
tor); Lawrence W. Svenson, B.Sc. (University of Alberta,
Collaborator); Patricia Caetano, Ph.D. (University of Manitoba,
Collaborator); Nathalie Jette, MD, M.Sc., FRCPC (University of
Calgary, Site Investigator).
Compliance with ethical standards
Conflicts of interest Dr. Kingwell, Mr. Zhu, Dr. Profetto-McGrath
and Mr. Svenson report no disclosures.
Dr. Marrie receives research funding from: Canadian Institutes of
Health Research, Public Health Agency of Canada, Manitoba Health
Research Council, Health Sciences Centre Foundation, Multiple
Sclerosis Society of Canada, Multiple Sclerosis Scientific Foundation,
Rx&D Health Research Foundation, and has conducted clinical trials
funded by sanofi-aventis.
Dr. Fisk receives research funding from: Canadian Institutes of Health
Research, Multiple Sclerosis Society of Canada and the National MS
Society (USA).
Dr. Wolfson receives funding from: Canadian Institutes of Health
Research, Canada Foundation for Innovation, Multiple Sclerosis
Society of Canada, National Multiple Sclerosis Society, Research
Institute of the McGill University Health Centre.
Dr. Warren receives funding from Canadian Institutes of Health
Research and Fort Assiniboine Equine Endeavour Foundation.
Dr. Jette is the holder of a Canada Research Chair in Neurological
Health Sciences and an Alberta Innovates Health Solutions (AI-HS)
Population Health Investigator Award. She receives research funding
from the Canadian Institutes of Health Research, AI-HS, Hotchkiss
Brain Institute, Cumming School of Medicine, University of Calgary,
Alberta Health Services and Alberta Health.
Dr. Bhan has received honoraria and consulting fees from Biogen
Idec, EMD Serono, Genzyme, Novartis, Roche and Teva Neuro-
sciences.
Dr. Yu receives research funding from: Health Science Centre
J Neurol (2015) 262:2352–2363 2361
123
Foundation, Canadian Institutes of Health Research, Gilead Sciences,
Canadian International Development Agency, Multiple Sclerosis
Society of Canada, and National Multiple Sclerosis Society.
Dr. Elliott receives research funding from the Canadian Institutes of
Health Research and the Multiple Sclerosis Society of Canada.
Dr. Tremlett is funded by the Multiple Sclerosis Society of Canada
(Don Paty Career Development Award); is a Michael Smith Foun-
dation for Health Research Scholar and the Canada Research Chair
for Neuroepidemiology and Multiple Sclerosis. She has received:
research support from the National Multiple Sclerosis Society, the
Canadian Institutes of Health Research, and the UK MS Trust;
speaker honoraria and/or travel expenses to attend conferences from
the Consortium of MS Centres (2013), the National MS Society
(2012, 2014), Bayer Pharmaceuticals (2010), Teva Pharmaceuticals
(2011), ECTRIMS (2011, 2012, 2013, 2014), UK MS Trust (2011),
the Chesapeake Health Education Program, US Veterans Affairs
(2012), Novartis Canada (2012), Biogen Idec (2014), American
Academy of Neurologists (2013, 2014). Unless otherwise stated, all
speaker honoraria are either donated to an MS charity or to an
unrestricted grant for use by her research group.
On behalf of all coauthors, the corresponding author states that there
is no conflict of interest specific to this study.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Multiple Sclerosis International Federation (2013) Atlas of MS.
http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.
pdf. Accessed 8 December 2014
2. Evans C, Beland SG, Kulaga S, Wolfson C, Kingwell E, Marriott
J et al (2013) Incidence and prevalence of multiple sclerosis in
the Americas: a systematic review. Neuroepidemiology
40(3):195–210
3. Kingwell E, Marriott JJ, Jette N, Pringsheim T, Makhani N,
Morrow SA et al (2013) Incidence and prevalence of multiple
sclerosis in Europe: a systematic review. BMC Neurol 13(1):128
4. Makhani N, Morrow SA, Fisk JD, Evans C, Beland SG, Kulaga S
et al (2014) MS incidence and prevalence in Africa, Asia, Aus-
tralia and New Zealand: a systematic review. Mult Scler Relat
Disord 3:48–60
5. Alonso A, Hernan MA (2008) Temporal trends in the incidence
of multiple sclerosis: a systematic review. Neurology
71(2):129–135
6. Koch-Henriksen N, Sorensen PS (2010) The changing demo-
graphic pattern of multiple sclerosis epidemiology. Lancet Neurol
9(5):520–532
7. Trojano M, Lucchese G, Graziano G, Taylor BV, Simpson S Jr,
Lepore V et al (2012) Geographical variations in sex ratio trends
over time in multiple sclerosis. PLoS One 7(10):e48078
8. Public Health Agency of Canada (2014) Preventing Chronic
Disease Strategic Plan 2013-2016. http://www.phac-aspc.gc.ca/
cd-mc/diabetes-diabete/strategy_plan-plan_strategique-eng.php.
Accessed 29 September 2014
9. The National MS Society (2014) MS Prevalence. http://www.
nationalmssociety.org/About-the-Society/MS-Prevalence. Acces-
sed 29 September 2014
10. Marrie RA, Yu N, Blanchard J, Leung S, Elliott L (2010) The
rising prevalence and changing age distribution of multiple
sclerosis in Manitoba. Neurology 74(6):465–471
11. Marrie RA, Fisk JD, Stadnyk KJ, Yu BN, Tremlett H, Wolfson C
et al (2013) The incidence and prevalence of multiple sclerosis in
nova scotia, Canada. Can J Neurol Sci 40(6):824–831
12. British Columbia Ministry of Health [creator] (2012) Discharge
Abstract Database (Hospital Separations). Population Data BC
[publisher]. Data Extract. MOH (2012). http://www.popdata.bc.
ca/data
13. British Columbia Ministry of Health [creator] (2012) Medical
Services Plan (MSP) Payment Information File Population Data
BC [publisher]. Data Extract. MOH (2012). http://www.popdata.
bc.ca/data
14. British Columbia Ministry of Health [creator] (2012). Phar-
maNet: BC Ministry of Health [publisher]; 2012. Data Extract
MOH (2012). http://www.popdata.bc.ca/data
15. BC Vital Statistics Agency [creator] (2012). Vital Statistics
Deaths: Population Data BC [publisher]. Data Extract. MOH
(2012). http://www.popdata.bc.ca/data
16. British Columbia Ministry of Health [creator] (2012) Consoli-
dation File (MSP Registration & Premium Billing). Population
Data BC [publisher]. Data Extract. MOH (2012). http://www.
popdata.bc.ca/data
17. Statistics Canada (2014) Annual Income Estimates for Census
Families and Individuals (T1 Family File). http://www23.statcan.
gc.ca/imdb/p2SV.pl?Function=getSurvey&SDDS=4105&lang=
en&db=IMDB&dbg=f&adm=8&dis=2. Accessed 11 August
2014
18. Widdifield J, Ivers NM, Young J, Green D, Jaakkimainen L, Butt
DA et al (2014) Development and validation of an administrative
data algorithm to estimate the disease burden and epidemiology
of multiple sclerosis in Ontario, Canada. Mult Scler. doi:10.1177/
1352458514556303
19. Hader WJ, Yee IM (2007) Incidence and prevalence of multiple
sclerosis in Saskatoon, Saskatchewan. Neurology
69(12):1224–1229
20. Fay MP, Feuer EJ (1997) Confidence intervals for directly stan-
dardized rates: a method based on the gamma distribution. Stat
Med 16(7):791–801
21. Beck CA, Metz LM, Svenson LW, Patten SB (2005) Regional
variation of multiple sclerosis prevalence in Canada. Mult Scler.
11(5):516–519
22. Sweeney VP, Sadovnick AD, Brandejs V (1986) Prevalence of
multiple sclerosis in British Columbia. Can J Neurol Sci
13(1):47–51
23. Mackenzie IS, Morant SV, Bloomfield GA, MacDonald TM,
O’Riordan J (2014) Incidence and prevalence of multiple scle-
rosis in the UK 1990–2010: a descriptive study in the General
Practice Research Database. J Neurol Neurosurg Psychiatry
85(1):76–84
24. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP,
Lublin FD et al (2001) Recommended diagnostic criteria for
multiple sclerosis: guidelines from the International Panel on the
diagnosis of multiple sclerosis. Ann Neurol. 50(1):121–127
25. Warren SA, Svenson LW, Warren KG (2008) Contribution of
incidence to increasing prevalence of multiple sclerosis in
Alberta. Canada. Mult Scler 14(7):872–879
26. Sloka JS, Pryse-Phillips WE, Stefanelli M (2005) Incidence and
prevalence of multiple sclerosis in Newfoundland and Labrador.
Can J Neurol Sci 32(1):37–42
27. Kingwell E, van der Kop M, Zhao Y, Shirani A, Zhu F, Oger J
et al (2012) Relative mortality and survival in multiple sclerosis:
findings from British Columbia, Canada. J Neurol Neurosurg
Psychiatry 83(1):61–66
2362 J Neurol (2015) 262:2352–2363
123
28. Bronnum-Hansen H, Koch-Henriksen N, Stenager E (2004)
Trends in survival and cause of death in Danish patients with
multiple sclerosis. Brain 127(Pt 4):844–850
29. Grytten Torkildsen N, Lie S, Aarseth J, Nyland H, Myhr K (2008)
Survival and cause of death in multiple sclerosis: results from a
50-year follow-up in Western Norway. Mult Scler
14(9):1191–1198
30. Lowis GW (1990) The social epidemiology of multiple sclerosis.
Sci Total Environ 90:163–190
31. Kurtzke JF, Page WF (1997) Epidemiology of multiple sclerosis
in US veterans: VII. Risk factors for MS. Neurology
48(1):204–213
32. Zilber N, Kahana E (1996) Risk factors for multiple sclerosis: a
case-control study in Israel. Acta Neurol Scand 94(6):395–403
33. Hammond SR, McLeod JG, Macaskill P, English DR (1996)
Multiple sclerosis in Australia: socioeconomic factors. J Neurol
Neurosurg Psychiatry 61(3):311–313
34. Green C, Yu BN, Marrie RA (2013) Exploring the implications of
small-area variation in the incidence of multiple sclerosis. Am J
Epidemiol 178(7):1059–1066
35. Goulden R, Ibrahim T, Wolfson C (2015) Is high socioeconomic
status a risk factor for multiple sclerosis? A systematic review.
Eur J Neurol 22(6):899–911
36. Karampampa K, Gustavsson A, Miltenburger C, Kindundu CM,
Selchen DH (2012) Treatment experience, burden, and unmet
needs (TRIBUNE) in multiple sclerosis: the costs and utilities of
MS patients in Canada. J Popul Ther Clin Pharmacol 19(1):e11–
e25
37. Amed S, Vanderloo SE, Metzger D, Collet JP, Reimer K, McCrea
P et al (2011) Validation of diabetes case definitions using
administrative claims data. Diabet Med 28(4):424–427
38. Quan H, Khan N, Hemmelgarn BR, Tu K, Chen G, Campbell N
et al (2009) Validation of a case definition to define hypertension
using administrative data. Hypertension 54(6):1423–1428
39. Government of Canada (2015) Canadian Chronic Disease
Surveillance System 1999/2000-2010/2011 Ottawa 2014. http://
data.gc.ca/data/en/dataset/9525c8c0-554a-461b-a763-
f1657acb9c9d. Accessed 23 June 2015
40. Statistics Canada (1996) Census: Ethnic origin, visible minorities.
Ottawa 1998. http://www.statcan.gc.ca/daily-quotidien/980217/
dq980217-eng.htm. Accessed 9 December 2014
41. Statistics Canada (2006) Canada’s Ethnocultural Mosaic, 2006
Census: Provinces and territories. Ottawa. http://www12.statcan.
ca/census-recensement/2006/as-sa/97-562/index-eng.cfm?CFID=
124733&CFTOKEN=71329601. Accessed 9 December 2014
J Neurol (2015) 262:2352–2363 2363
123
